Egrifta (tesamorelin)
- Region
- 🇪🇺 EU
- Active substance
- tesamorelin
- Company
- Ferrer Internacional S.A.
- Status
- Application withdrawn
- Application
- EMEA/H/C/002427
- Official record
- www.ema.europa.eu
Indication
Treatment of excess abdominal fat in HIV-infected patients with lipodystrophy
Regulatory milestones
No milestones recorded in the last year.
Follow Egrifta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.